Alcresta is a specialty pharmaceutical company that is developing innovative and proprietary enzyme based products for people suffering from compromised pancreatic function such as exocrine pancreatic insufficiency (EPI) or nutrient malabsorption. 

Read more

Alcresta Appoints Russell Clayton, D.O., Chief Medical Officer

Read More >

Alcresta Presents New Data Demonstrating Potential of Proprietary Enzyme-Based Technology to Improve Nutrition in Patients with Exocrine Pancreatic Insufficiency

Read More >